Medicine Man Technologies, Inc.

SHWZ

$62M

Micro Cap

NASDAQServices-Management Consulting Services🇺🇸North AmericaDENVER

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 28, 2026

20d

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

INS018_055 Phase 2 Results Expected

Feb 28, 2026INS018_05540

Primary completion for INS018_055 trial (NCT05975983) in Idiopathic Pulmonary Fibrosis (IPF)

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

NFC-1

Phase 3

Attention Deficit Disorder With Hyperactivity

AEVI-001

Phase 2

Attention Deficit Hyperactivity Disorder

CERC-002

Phase 2

COVID-19 Pneumonia

MDGN201 TARGTEPO

Phase 2

Chronic Kidney Disease

HMI-115-120mg-Q4W

Phase 2

Androgenetic Alopecia

HMI-115

Phase 2

Endometriosis

INS018_055

Phase 2

Idiopathic Pulmonary Fibrosis (IPF)

ISM5411 tablets

Phase 2

Ulcerative Colitis

Drug Name	Phase	Indication	Designations
NFC-1	Phase 3	Attention Deficit Disorder With Hyperactivity	-
AEVI-001	Phase 2	Attention Deficit Hyperactivity Disorder	-
CERC-002	Phase 2	COVID-19 Pneumonia	-
MDGN201 TARGTEPO	Phase 2	Chronic Kidney Disease	-
HMI-115-120mg-Q4W	Phase 2	Androgenetic Alopecia	-
HMI-115	Phase 2	Endometriosis	-
INS018_055	Phase 2	Idiopathic Pulmonary Fibrosis (IPF)	-
ISM5411 tablets	Phase 2	Ulcerative Colitis	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

SHWZ News